Azenta, Inc.

Fundamentals4.0
Price Action2.0
News Sentiment2.0
AI Rating
3.0

Key Drivers

  • Cash Flow
  • Margin Compression
  • Low Leverage

AI
AI Summary

3.0

AZTA is now best viewed as an execution-repair story rather than a turnaround, since the guidance cut, margin compression, and goodwill impairment show prior assumptions were too aggressive, even though cash generation and a debt-free balance sheet still give it time to fix operations; the key question is whether management can stabilize recurring-revenue margins before further de-rating.

ExecutionRisk
GuidanceCut
BalanceSheet‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

4.0

Key Financial Insights:

  • Cash Flow
  • Margin Compression
  • Low Leverage

AZTA has solid liquidity, low leverage, and continued cash flow, but persistent losses and a sharp quarterly margin collapse make the stock financially fragile despite a compressed valuation.

Liquidity
Losses

Price Behavior

2.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Broken support
  • Oversold bounce

Over the last month, AZTA has dropped about 36% into a clear downtrend with lower highs and broken support, leaving only an oversold bounce setup near $16.00 while resistance sits at $18.50-$19.25 and a stronger recovery would require reclaiming $24-$25.

bearish
oversold
Support Level: $16.00
Resistance Level: $18.50-$19.25

Sharp decline from $25.04 to $16.02 after a breakdown from the $24-$26 area

Sentiment & News

2.0

Key News Insights:

  • Guidance reset
  • Goodwill impairment
  • Legal scrutiny

Azenta's Q2 update sharply cut FY2026 growth and margin guidance, added a $149M goodwill impairment, and quickly triggered shareholder-law investigations after the stock's post-earnings drop.

Azenta
Earnings

The news is likely negative for Azenta, as weaker outlook and impairment concerns may keep pressure on the stock until visibility improves